Three discipline collaborative radiation therapy (3DCRT) special debate: I would treat all early-stage NSCLC patients with SBRT 1 | THREE DISCIPLINE COLLABORATIVE
engaging for the readership but will also foster further collaboration in the science and clinical practice of radiation oncology.
| INTRODUCTION
Stereotactic Body Radiotherapy (SBRT) has emerged as an effective treatment for early-stage inoperable Non-Small Cell Lung Cancer (NSCLC) patients. We currently have strong evidence for the safety and efficacy of SBRT for patients with tumors outside of the proximal tracheobronchial tree. As SBRT gains more widespread use, evidence is beginning to mount which not only supports the safety of SBRT for centrally located lesions, but also suggests that SBRT may be a viable alternative to surgery for operable patients. SBRT may offer the possibility of local control and long-term survival similar to surgery, but with decreased procedural morbidity, therefore improved quality of life (QoL) for such patients. However, surgery currently remains the standard of care for the treatment of resectable, early-stage NSCLC. SBRT has thus far demonstrated significant efficacy and the ability to reduce the risk of complications for some patients, but can we yet make a convincing case for SBRT as the In the case of surgery, current options for early-stage NSCLC include lobectomy for patients deemed completely operable (CO) or sub-lobar resection for those deemed marginally operable (MO). The benchmark Lung Cancer Study Group clinical study in T1N0 NSCLC patients noted that, compared to lobectomy, sub-lobar resection had a 75% increased recurrence rate (P = 0.008) and a 30% increase in overall death rate (P = 0.08) without improvement in perioperative morbidity, mortality, or late postoperative pulmonary function. 3 These findings indicate that MO patients, who cannot undergo lobectomy, may be strong candidates for SBRT. Whereas conventional thoracotomy for lobectomy is associated with poor postoperative quality of life (QoL); the modern surgical technique of videoassisted thoracoscopic surgery (VATS) has shown significant reduction in postoperative pain and improved recovery in a recent randomized controlled trial. 4 A recent Swedish nationwide cohort study demonstrated a 5-yr overall survival (OS) of 78% with VATS. 5 In the case of SBRT, multiple studies have shown comparable OS and superior QoL to lobectomy. Among the largest experiences of long-term outcomes, a Japanese multi-institutional study with 87 CO patients who refused surgery and were treated with SBRT, demonstrated 5-yr OS of 78%. 6 In a follow-up update of 661 operable patients, a 3-yr OS of 79% was noted. 7 A pooled analysis of two randomized trials (STARS and ROSEL) showed significantly superior 3-yr OS for SBRT compared to surgery (95% vs 79%, P < 0.05) with 10% vs 44% grade 3/4 treatment-related toxicity. 8 Third, there may be a biological basis that could also swing the pendulum in favor of SBRT. In an institutional analysis, SBRT treatments were noted to deliver an incidental mediastinal dose of <5 Gy of the prescription dose for the majority of patients. 13 Yet, the 4.9%
incidence of mediastinal recurrence was lower than that would be expected historically, raising the hypothesis of distant immune effects with the use of SBRT. Indeed, the possibility of tumor antigen presentation with ablative treatments and its impact on immunotherapeutic treatments is yet to be fully explored, 14 and there are ongoing clinical trials combining SBRT with immunotherapy in lung cancer. [15] [16] [17] Note that head-to-head retrospective comparisons of surgery and SBRT are limited (and arguably biased against SBRT) due to primary use of SBRT for medically inoperable patients. These patients present with existing comorbidities, confounding the survival outcome. There is also stage-migration in favor of surgical series, which exclude patients with nodal disease in the surgical specimen. This is especially relevant for population-based analyses which have shown conflicting results between surgery and SBRT even when using propensity score analysis. [18] [19] [20] Indeed, one analysis of medically operable vs inoperable patients treated with SBRT has also demonstrated lower OS in the latter group. 21 Data on an intent-to-treat analysis of surgery vs SBRT are also lacking.
A common rationale employed to justify surgery over SBRT is the low risk of postoperative complications including deaths with VATS surgery. Nonetheless, it is important to note that in the most recent randomized assessment from a large Dutch group, clinically relevant pain in the first 24 h was seen in 38% of the VATS patients with 9.2% (7/76) patients continuing to note moderate to severe pain even at 52-weeks follow up. Postoperative grade 3-4 events were noted in 23.5% (24/102) patients. In comparison, in the Japanese multi-institutional SBRT experience, grade 3 or greater complications were noted in 1.9% patients with 0.5% treatment-related deaths. 7 One limitation of SBRT is the lack of formal surgical nodal staging which results in inclusion of patients with micrometastatic disease, resulting in higher rates of regional recurrence in comparison to surgery. 22 Use of modern endobronchial ultrasound and PET-CTbased staging may reduce this disparity. Additional research with the use of circulating tumor cell assessment in presumed early-stage NSCLC may also provide lead-time notice of disease recurrence or progression. 23 Finally, with the use of modern treatment paradigms, salvage of isolated nodal failure is feasible. 24, 25 On the other hand, a significant limitation of surgery is the management of patients presenting with more than one synchronous or metachronous lesion. While lobectomy may be feasible for one lesion, a second lobectomy will generally not be preferred. doses seem to be dominated by the response of the hypoxic cell subpopulation in the tumor, which may change the assumed tumor α/β ratios that are based on well-oxygenated cells. 47 Given that hypoxia is associated with poor prognosis, including for early-stage NSCLC 48, 49 and poor response to radiation therapy, 50 this is an aspect that needs In conclusion, taking into account the information currently available through randomized clinical trials and the lack of long-term survival data, the use of SBRT for all early-stage patients is not justified, and surgery should remain the gold standard for patients without comorbidities who can tolerate surgery. Robert Griffin, PhD
Both teams agree that for medically inoperable early-stage NSCLC patients, SBRT should be the treatment of choice. Our disagreement is whether SBRT should also be recommended as the first option, rather than surgery, to operable patients.
In their opening statement, the opposing team bases their arguments on an almost literal interpretation of the word "all." As clinicians and scientists, we can all agree that no medical intervention can claim applicability to "all" patients -there will always be excep- First, we agree with our opponents that evidence from randomized controlled trials (RCTs) is sorely needed. Most of the current debate surrounding this issue is guided by retrospective analyses.
Our opponents acknowledge that these retrospective studies have significant limitations, the chief among them being selection bias. For example, in the 2016 NCDB analysis which showed superior overall survival (OS) with surgery, there were significant limitations including lack of cancer-specific outcomes (local/regional/distant control), longer time from diagnosis to treatment in the SBRT cohort (72 vs 33 days, P < 0.001) and higher use of adjuvant chemotherapy in the lobectomy cohort (12% vs, 2%) either for pathological nodes (12%), larger tumors or positive margins. 18 Indeed, among other studies cited by our opponents, with appropriate use of propensity scorematching, SBRT showed performance similar or superior to surgery. 19, 20 Further, salvage of a failure is always more challenging than treating adjuvantly, which confounds the analysis for SBRT nodal failures. Such SBRT eligible patients could benefit from more standardized staging such as EBUS + PET-CT or adjuvant chemotherapy post-SBRT for higher risk tumors (larger than 5 cm or central) as suggested in many experiences including a recent NCDB analysis. 52 Notably, the only available data analysis to date from prospective randomized trials (pooled STARS/ROSEL) supports SBRT over surgery. 8 At best, the evidence to date points toward equipoise between the two modalities. For these reasons, we believe that unless evidence from RCTs comes out unequivocally in favor of surgery, SBRT, due to its noninvasive nature and overall convenience to the patient, should be considered the primary treatment option rather than surgery.
Second, we disagree with our opponents' statement "it is not safe to treat tumors located more centrally and close to critical 38 Additional challenges include the comparison of surgery to SBRT as it remains inherently difficult to control for the effect of comorbidities between the surgery-eligible and non-eligible patients. 59 In a retrospective study, a matched comparison based on age, tumor size, location, and comorbidities showed that the 3-yr OS was better in the surgery group compared to SBRT. [59] [60] [61] Hence, while important insights have been gained from these studies, challenges remain with respect to determining the optimal dose-response relationship that results in improved survival with minimal toxicities, as well as in appropriate comparisons between the benefits of surgery vs SBRT in patients that differ in age, tumor size and location and other related comorbidities. 62 Furthermore, studies also show that regardless of whether SBRT is a viable option for larger tumors, such tumors seem to be associated with more distant failures, thus needing extensive staging and adjuvant therapy. 63, 64 As Drs. Mohindra, Griffin and Sawant pointed out, there is a surge of prospective clinical trials comparing the effectiveness of SBRT with surgery in NSCLCs. These trials are still accruing patients or have closed due to the lack of accrual. While compelling evidence exists, the data collected so far are inconclusive and await maturation. The conclusions from these trials are crucial and the field should await the results before changing the standard of care to offer SBRT to all early-stage NSCLC patients purely based on QoL and convenience.
